Tessera Therapeutics, a Cambridge, Mass.-based early-stage life sciences company founded by Flagship Pioneering, raised over $230M in Series B financing.
The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, with participation from Qatar Investment Authority (QIA) and others.
The company intends to use thhe funds to accelerate research and development in its Gene Writing technologies, expand its team, and establish manufacturing and automation capabilities critical for its platform and programs.
Led by Geoffrey von Maltzahn, CEO and Co-Founder. and Noubar Afeyan, Chairman and Co-Founder, Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source with applications in cardiovascular, oncological, neurodegenerative, and infectious diseases.